MARC Record from marc_columbia

LEADER: 03479mam a2200397 a 4500
001 4049509
005 20221027024447.0
008 950607s1995 gw a b 001 0 eng c
010 $a 95024188
020 $a3805561636 (hardcover : alk. paper)
035 $a(OCoLC)ocm32822150
035 $9AKZ9661HS
035 $a4049509
040 $aDNLM/DLC$cDLC$dNLM$dNNC-M$dOrLoB
050 00 $aRM260$b.A55 vol. 47$aRM666.C379
060 10 $aW1$bAN855G v.47 1995
060 10 $aQV 350.5.C3$bO63 1995
082 00 $a615.5/8 s$a615/.32924$220
245 00 $aOral cephalosporins /$cvolume editor, R.C. Moellering, Jr.
260 $aBasel ;$aNew York :$bKarger,$c1995.
300 $aix, 189 pages :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aAntibiotics and chemotherapy ;$vvol. 47
504 $aIncludes bibliographical references and index.
505 00 $tSystematics of Beta-Lactams: Chemical Properties and Structure Activity Relationship of Oral Cephalosporins /$rF. Kees and H. Grobecker --$tPharmacology and Toxicology of Oral Cephalosporins /$rG. Gialdroni Grassi --$tClinical Pharmacokinetics of Oral Cephalosporins /$rK. Stoeckel, W. L. Hayton and D. J. Edwards --$tMicrobiology of Oral Cephalosporins /$rW. Cullmann --$tOral Cephalosporins in Upper Respiratory Infections /$rE. Leibovitz and R. Dagan --$tOral Cephalosporins: Clinical Results in Lower Respiratory Tract Infections /$rE. Pozzi and A. Oliva --$tOral Cephalosporins: Clinical Results in Urinary Tract Infections /$rH. Giamarellou --$tTolerability of Oral Cephalosporins /$rH. Lepper and C.-J. Estler.
520 $aThis volume provides an excellent survey of the chemistry, microbiology, pharmacology and clinical use of the oral cephalosporins in general and the newer agents in particular. The cephalosporins have long provided satisfactory treatment for many disorders without causing serious side effects; and over the past fifty years forms with different antimicrobial, pharmacologic and toxicologic properties have been developed.
520 8 $aDespite the broad spectrum of their activity against a large variety of gram-positive and gram-negative bacteria, the third-generation oral cephalosporins including the prodrug esters do not work against Pseudomonas aeruginosa, methicillin-resistant staphylococci, enterococci or Bacteroides species. Many, however, are suitable for treating infections of the respiratory and urinary tracts and of the skin and its structure, as well as certain sexually-transmitted diseases.
520 8 $aAuthors consider other possible uses, against multi-resistant Enterobacteriaceae for instance, but also point out the limitations of the oral cephalosporins. For those working in the fields of infectious disease, bacteriology, chemotherapy, pharmaceutics and pharmacokinetics, this book is a valuable source of authoritative information.
650 0 $aCephalosporins.$0http://id.loc.gov/authorities/subjects/sh85021981
650 12 $aCephalosporins$xadministration & dosage.$0https://id.nlm.nih.gov/mesh/D002511Q000008
650 12 $aCephalosporins$xpharmacology.$0https://id.nlm.nih.gov/mesh/D002511Q000494
650 22 $aAdministration, Oral.$0https://id.nlm.nih.gov/mesh/D000284
700 1 $aMoellering, Robert C.$0http://id.loc.gov/authorities/names/n85029416
830 0 $aAntibiotics and chemotherapy ;$vv. 47.$0http://id.loc.gov/authorities/names/n84705863
852 80 $boff,hsr$hSerial$iA